Summary
Adding copanlisib, a PI3K inhibitor, to rituximab significantly improved outcomes for patients with relapsed indolent non-Hodgkin lymphoma. This combination therapy nearly halved the risk of disease progression or death in the CHRONOS-3 trial.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Indolent non-Hodgkin lymphoma (iNHL) is a type of B-cell lymphoma.
- Relapsed iNHL often requires novel therapeutic strategies.
- Standard treatment for relapsed iNHL includes rituximab, but outcomes can be improved.
Purpose of the Study:
- To evaluate the efficacy and safety of adding copanlisib to rituximab in patients with relapsed iNHL.
- To assess the impact of this combination on disease progression and overall survival.
Main Methods:
- Phase III CHRONOS-3 trial.
- Randomized, double-blind, placebo-controlled study.
- Patients received either copanlisib plus rituximab or placebo plus rituximab.
Main Results:
- The combination of copanlisib and rituximab significantly reduced the risk of disease progression or death by nearly half compared to placebo and rituximab.
- The treatment combination demonstrated a favorable safety profile.
- Copanlisib, a pan-PI3K inhibitor, showed significant benefit in this patient population.
Conclusions:
- Adding copanlisib to rituximab is a safe and effective treatment option for patients with relapsed indolent non-Hodgkin lymphoma.
- This combination therapy represents a significant advancement in the treatment of relapsed iNHL.
- Further research may explore optimal sequencing and combination strategies.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.7K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.7K
Related Concept Videos
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:23Abnormal Proliferation
4.8K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
02:50Combination Therapies and Personalized Medicine
5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
02:07Tumor Progression
6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K